| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3927 |
| Trial ID | NCT06482684 |
| Disease | Mantle Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KTE-X19|Tecartus|Brexucabtagene autoleucel |
| Co-treatment | Ibrutinib|Rituximab |
| Location approved | US, EU, UK, Australia, Canada |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Early Treatment Intensification in Patients With High Risk Mantle Cell Lymphoma Using CAR-T-cell Treatment After an Abbreviated Induction Therapy With Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) as Compared to Standard of Care Induction and Maintenance (Arm B) |
| Year | 2024 |
| Country | Germany |
| Company sponsor | Christian Schmidt, MD |
| Other ID(s) | CARMAN|2022-502405-15-01 |
| Cohort 1 | |||||||||
|
|||||||||